Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
AGS62P1 is a human anti-FLT3 antibody in conjugation with a microtubule disrupting agent, which may have anti-tumor activity (Blood 2015 126(23):3806).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AGS62P1||AGS62P1 is a human anti-FLT3 antibody in conjugation with a microtubule disrupting agent, which may have anti-tumor activity (Blood 2015 126(23):3806).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 positive||acute myeloid leukemia||predicted - sensitive||AGS62P1||Preclinical - Patient cell culture||Actionable||In a preclinical study, AGS62P1 inhibited growth of FLT3-positive acute myeloid leukemia cell lines in culture, and led to tumor growth inhibition and regression in patient-derived xenograft (PDX) models (Blood 2015 126(23):3806).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02864290||Phase I||AGS62P1||A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)||Recruiting|